Novel approach for treatment of Parkinson's disease

Lario Therapeutics awarded $6M Grant from The Michael J. Fox Foundation for Parkinson’s Research

24-Jul-2024 - Lario Therapeutics, a biopharmaceutical company developing first-in-class precision medicines for epileptic and neurological disorders, announced it has been awarded a $6 million USD grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The programme is in collaboration with ...

Biotie awarded USD 2 million grant from The Michael J. Fox Foundation

09-Jul-2014 - Biotie Therapies has signed a USD 2 million research contract with The Michael J. Fox Foundation (MJFF) to investigate SYN120 in Parkinson's disease patients with dementia. SYN120 is a dual antagonist of 5-HT6 and 5-HT2a receptors and these two distinct modes of action could result in a unique ...

Cynapsus Therapeutics Awarded Grant from The Michael J. Fox Foundation for Clinical Examination of APL-130277

09-Aug-2012 - Cynapsus Therapeutics Inc. announced that it has been awarded a grant of USD$947,925 from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to support clinical studies to develop APL-130277, a sublingual (oral) thin film strip reformulation of apomorphine. Apomorphine is an approved ...

to-BBB receives Michael J. Fox Foundation funding for Parkinson’s disease research

24-Apr-2012 - to-BBB has been awarded funding by The Michael J. Fox Foundation (MJFF) to conduct preclinical research targeting neuroinflammation in Parkinson’s disease (PD) with its second product in development, 2B3-201. This is to-BBB’s first grant from MJFF.“We strongly believe that we can create better ...

The Michael J. Fox Foundation Awards AFFiRiS $1.5 Million for the Clinical Development of the First Parkinson’s Disease Vaccine

14-Oct-2011 - The Michael J. Fox Foundation (MJFF) announced that it has awarded $1.5 million to AFFiRiS AG for a clinical study of AFFITOPE® PD01, a first-of-its-kind Parkinson’s disease (PD) vaccine. AFFITOPE® PD01 targets and helps remove the alpha-synuclein protein, whose clumping is the pathological ...

BioFocus enters collaboration with Michael J. Fox Foundation

15-Jul-2011 - BioFocus announced that it has signed a collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research, a not-for-profit organization focused on developing therapies for Parkinson’s disease. Under the agreement, BioFocus will perform fragment-based screening, assay ...

Allon receives Michael J. Fox Foundation grant for Parkinson’s disease research

02-Dec-2010 - Allon Therapeutics Inc. announced it has received a major grant from the Michael J. Fox Foundation (MJFF) for Parkinson’s Research to conduct pre-clinical research that will help determine the potential of the Company’s lead neuroprotective drug, davunetide, as a treatment for Parkinson’s disease ...

Addex Awarded Michael J. Fox Foundation Grant for ADX48621 to treat Levodopa-Induced Dyskinesia in Parkinson's

10-Sep-2010 - Addex Pharmaceuticals Ltd announced that it has been awarded a $900,000 grant from the Michael J. Fox Foundation (MJFF) to help fund a Phase II study of ADX48621 for the treatment of Parkinson’s disease levodopa-induced dyskinesia (PD-LID). Patients with PD can live 10-20 years after diagnosis; ...

InterMed Discovery Receives Michael J. Fox Foundation Award for IMD-026259

21-Jan-2010 - InterMed Discovery (IMD) announced that it has received an award from The Michael J. Fox Foundation for Parkinson’s Research for its programme to develop IMD-026259 as a pharmaceutical treatment to challenge neuro-degeneration in Parkinson’s disease (PD). PD is a disease of progressive ...

Michael J. Fox Foundation Awards $2 Million Grant from Merck Serono to Research Projects on Parkinson's Disease

Five Research Teams Selected to Receive Funding for Preclinical and

16-Oct-2008 - The Michael J. Fox Foundation for Parkinson's Research (MJFF) awarded a total of$2 million to five research teams to speed development of effective therapies for the under-addressed cognitive and mood-related symptoms of Parkinson's disease (PD). The award was made possible by leadership funding ...